Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567774 | 0.83 | CYP19A1 (0.53) | CYP4F2CYP4A11MAOBMRGPRX4NR4A2 | |
| SCHEMBL2570251 | 0.81 | CSNK2A1 (0.47) | CFDMAOBMAPK1TDP1CYP19A1 | |
| SCHEMBL2573344 | 0.80 | CSNK2A1 (0.54) | CFDMAOBMRGPRX4PTGER1GSTP1 | |
| SCHEMBL2006949 | 0.80 | MAOB (0.56) | CYP4F2CYP4A11MAOBMAPTKDM4E | |
| SCHEMBL16501385 | 0.78 | MAOB (0.43) | CYP4F2CYP4A11MAOBKDM4EMAPK1 | |
| SCHEMBL2567693 | 0.76 | CCR6 (0.48) | CFDKDM4ECYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2570119 | 0.75 | MAOB (0.65) | CFDCYP4F2CYP4A11MAOBMRGPRX4 | |
| SCHEMBL9453126 | 0.75 | CYP4F2 (0.64) | CYP4F2CYP4A11MAOBLTA4HEPHX2 | |
| SCHEMBL24675198 | 0.73 | PRSS1 (0.49) | CYP4F2CYP4A11MAOB | |
| SCHEMBL538599 | 0.73 | MAOB (0.70) | CYP4F2CYP4A11MAOBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1698635-B1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-12-14 | — | — | EP | disclosed |
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-7547680-B2 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICALS, CO., LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1698635-A1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | CFD 3412/4885CYP4F2 916/4885CYP4A11 502/4885 |
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | SLCO1B3, SLCO2A1, SLCO2B1 | CFD 3333/4885CYP4F2 251/4885CYP4A11 1003/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | CFD 3795/4885CYP4F2 726/4885CYP4A11 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.